Senseonics (NYSE:SENS) shares are up today on Q4 earnings ahead of the consensus forecast, with the company planning to launch its next-gen, implantable, 6-month CGM in the U.S next month.
The Germantown, Maryland-based company posted revenues of $4 million for the three months ended Dec. 31, 2021, representing sales growth of 2.6% from the same period in 2020.
Adjusted to exclude one-time items, earnings per share were 1¢, 4¢ ahead of expectations on Wall Street, where analysts were looking for sales of $4 million.
Get the full story at our sister site, Drug Delivery Business News.